Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock jumped 2.99% on Monday to $28.90 against a previous-day closing price of $28.06. With 0.88 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.99 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $29.16 whereas the lowest price it dropped to was $27.86. The 52-week range on ARWR shows that it touched its highest point at $42.48 and its lowest point at $22.87 during that stretch. It currently has a 1-year price target of $56.62. Beta for the stock currently stands at 0.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARWR was up-trending over the past week, with a rise of 11.28%, but this was up by 13.60% over a month. Three-month performance surged to 1.83% while six-month performance fell -20.87%. The stock lost -5.46% in the past year, while it has lost -28.75% so far this year. A look at the trailing 12-month EPS for ARWR yields -1.71 with Next year EPS estimates of -2.69. For the next quarter, that number is -0.61. This implies an EPS growth rate of 10.41% for this year and -80.04% for next year. EPS is expected to grow by 7.33% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -29.13%.
Float and Shares Shorts:
At present, 105.96 million ARWR shares are outstanding with a float of 100.98 million shares on hand for trading. On Oct 30, 2023, short shares totaled 7.17 million, which was 6.69% higher than short shares on Sep 28, 2023. In addition to Dr. Christopher R. Anzalone Ph.D. as the firm’s CEO, President & Director, Mr. Kenneth A. Myszkowski serves as its Chief Financial Officer.
Through their ownership of 70.74% of ARWR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 6.45% of ARWR, in contrast to 44.37% held by mutual funds. Shares owned by individuals account for 25.44%. As the largest shareholder in ARWR with 10.85% of the stake, BlackRock Fund Advisors holds 11,634,079 shares worth 11,634,079. A second-largest stockholder of ARWR, The Vanguard Group, Inc., holds 10,560,349 shares, controlling over 9.85% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in ARWR, holding 5,862,965 shares or 5.47% stake. With a 3.09% stake in ARWR, the iShares Core S&P Mid Cap ETF is the largest stakeholder. A total of 3,310,332 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 3.02% of ARWR stock, is the second-largest Mutual Fund holder. It holds 3,236,662 shares valued at 79.59 million. Vanguard Small Cap Index Fund holds 2.45% of the stake in ARWR, owning 2,628,987 shares worth 64.65 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARWR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ARWR analysts setting a high price target of $90.00 and a low target of $26.00, the average target price over the next 12 months is $56.62. Based on these targets, ARWR could surge 211.42% to reach the target high and fall by -10.03% to reach the target low. Reaching the average price target will result in a growth of 95.92% from current levels.
Summary of Insider Activity:
Insiders traded ARWR stock several times over the past three months with 1 Buys and 4 Sells. In these transactions, 57,755 shares were bought while 83,643 shares were sold. The number of buy transactions has increased to 17 while that of sell transactions has risen to 38 over the past year. The total number of shares bought during that period was 739,785 while 345,951 shares were sold.